Pathological and molecular mechanisms of prostate carcinogenesis

Implications for diagnosis, detection, prevention, and treatment

Research output: Contribution to journalArticle

Abstract

Prostate cancer is an increasing threat throughout the world. As a result of a demographic shift in population, the number of men at risk for developing prostate cancer is growing rapidly. For 2002, an estimated 189,000 prostate cancer cases were diagnosed in the U.S., accompanied by an estimated 30,200 prostate cancer deaths [Jemal et al., 2002]. Most prostate cancer is now diagnosed in men who were biopsied as a result of an elevated serum PSA (>4 ng/ml) level detected following routine screening. Autopsy studies [Breslow et al., 1977; Yatani et al., 1982; Sakr et al., 1993], and the recent results of the Prostate Cancer Prevention Trial (PCPT) [Thompson et al., 2003], a large scale clinical trial where all men entered the trial without an elevated PSA (

Original languageEnglish (US)
Pages (from-to)459-477
Number of pages19
JournalJournal of Cellular Biochemistry
Volume91
Issue number3
DOIs
StatePublished - 2004

Fingerprint

Prostate
Prostatic Neoplasms
Screening
Carcinogenesis
Therapeutics
Autopsy
Demography
Clinical Trials
Serum
Population

Keywords

  • Benign prostatic hyperplasia
  • Inflammation
  • Prostate cancer
  • Prostateatrophy
  • Prostatitis

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

@article{3c2cb7ff2d414d7cb5d0aa828b7e9957,
title = "Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment",
abstract = "Prostate cancer is an increasing threat throughout the world. As a result of a demographic shift in population, the number of men at risk for developing prostate cancer is growing rapidly. For 2002, an estimated 189,000 prostate cancer cases were diagnosed in the U.S., accompanied by an estimated 30,200 prostate cancer deaths [Jemal et al., 2002]. Most prostate cancer is now diagnosed in men who were biopsied as a result of an elevated serum PSA (>4 ng/ml) level detected following routine screening. Autopsy studies [Breslow et al., 1977; Yatani et al., 1982; Sakr et al., 1993], and the recent results of the Prostate Cancer Prevention Trial (PCPT) [Thompson et al., 2003], a large scale clinical trial where all men entered the trial without an elevated PSA (",
keywords = "Benign prostatic hyperplasia, Inflammation, Prostate cancer, Prostateatrophy, Prostatitis",
author = "Demarzo, {Angelo Michael} and Theodore DeWeese and Platz, {Elizabeth A} and Meeker, {Alan Keith} and Masashi Nakayama and Epstein, {Jonathan Ira} and Isaacs, {William B} and Nelson, {William G}",
year = "2004",
doi = "10.1002/jcb.10747",
language = "English (US)",
volume = "91",
pages = "459--477",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Pathological and molecular mechanisms of prostate carcinogenesis

T2 - Implications for diagnosis, detection, prevention, and treatment

AU - Demarzo, Angelo Michael

AU - DeWeese, Theodore

AU - Platz, Elizabeth A

AU - Meeker, Alan Keith

AU - Nakayama, Masashi

AU - Epstein, Jonathan Ira

AU - Isaacs, William B

AU - Nelson, William G

PY - 2004

Y1 - 2004

N2 - Prostate cancer is an increasing threat throughout the world. As a result of a demographic shift in population, the number of men at risk for developing prostate cancer is growing rapidly. For 2002, an estimated 189,000 prostate cancer cases were diagnosed in the U.S., accompanied by an estimated 30,200 prostate cancer deaths [Jemal et al., 2002]. Most prostate cancer is now diagnosed in men who were biopsied as a result of an elevated serum PSA (>4 ng/ml) level detected following routine screening. Autopsy studies [Breslow et al., 1977; Yatani et al., 1982; Sakr et al., 1993], and the recent results of the Prostate Cancer Prevention Trial (PCPT) [Thompson et al., 2003], a large scale clinical trial where all men entered the trial without an elevated PSA (

AB - Prostate cancer is an increasing threat throughout the world. As a result of a demographic shift in population, the number of men at risk for developing prostate cancer is growing rapidly. For 2002, an estimated 189,000 prostate cancer cases were diagnosed in the U.S., accompanied by an estimated 30,200 prostate cancer deaths [Jemal et al., 2002]. Most prostate cancer is now diagnosed in men who were biopsied as a result of an elevated serum PSA (>4 ng/ml) level detected following routine screening. Autopsy studies [Breslow et al., 1977; Yatani et al., 1982; Sakr et al., 1993], and the recent results of the Prostate Cancer Prevention Trial (PCPT) [Thompson et al., 2003], a large scale clinical trial where all men entered the trial without an elevated PSA (

KW - Benign prostatic hyperplasia

KW - Inflammation

KW - Prostate cancer

KW - Prostateatrophy

KW - Prostatitis

UR - http://www.scopus.com/inward/record.url?scp=3843052772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3843052772&partnerID=8YFLogxK

U2 - 10.1002/jcb.10747

DO - 10.1002/jcb.10747

M3 - Article

VL - 91

SP - 459

EP - 477

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 3

ER -